Skip to main content

CLINICAL TRIAL article

Front. Nutr.
Sec. Nutrition, Psychology and Brain Health
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1464526

Effects of fish oil supplementation on bone turnover markers in depression: a pilot study

Provisionally accepted
Feifei Wang Feifei Wang 1Hui Yuan Hui Yuan 2Kun Jin Kun Jin 2Hui Tang Hui Tang 2Jimin Guo Jimin Guo 3Chuan-Yue Wang Chuan-Yue Wang 1jindong chen jindong chen 2Fang Dong Fang Dong 1Lu Wang Lu Wang 1*
  • 1 Beijing Anding Hospital, Capital Medical University, Beijing, China
  • 2 Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China
  • 3 Beijing University of Chemical Technology, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Background and objective: There is a close correlation between bone loss, depression, and antidepressants. N-3 PUFA supplementation has been considered an effective add-on therapeutic approach in ameliorating bone loss and relieving depression. However, the adjunctive effect of n-3 PUFA on bone metabolism in participants with depression is still unknown. This is a pilot study to investigate the dynamics of bone metabolism in depression and evaluate the efficacy of fish oil on bone loss in depression.In this study, we focused on the change of bone turnover markers in depression, the effect of n-3 PUFA supplementation on bone turnover markers, and its association with clinical characteristics. A case-control study and a secondary analysis of a previously published randomized clinical trial (NCT03295708) that evaluates the efficacy of n-3 PUFA supplementation in venlafaxine-treated depressed participants have been included.The levels of PINP (z=-2.233, p=0.026) in depressed participants were significantly increased compared with healthy controls at baseline. The secondary analysis has shown significant differences exited on CTX (χ 2 =4.848, p=0.028) and OSTEOC (χ 2 =6.178, p=0.013) between n-3 PUFA and placebo group. The levels of CTX and OSTEOC (p<0.05) significantly decreased in the placebo group, which indicates that venlafaxine treatment reduces both bone formation and resorption markers. While the levels of OSTEOC and PINP were increased in the n-3 PUFA group (p<0.05). Moreover, the change in bone turnover markers showed consistency with clinical symptomatic outcomes.Participants with first-diagnosed, drug-naï ve depression show active bone formation. Venlafaxine decreases bone remodeling, while n-3 PUFA increases bone formation, bringing light to preventing and treating bone loss in depression.

    Keywords: Major Depressive Disorder, n-3 PUFA, Bone formation, Bone Resorption, bone loss

    Received: 14 Jul 2024; Accepted: 29 Nov 2024.

    Copyright: © 2024 Wang, Yuan, Jin, Tang, Guo, Wang, chen, Dong and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lu Wang, Beijing Anding Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.